EPHA2 and hereditary clear cell renal cell carcinoma: EphA2-derived epitopes can induce the elevated immunoreactivity of CD4+ and CD8+ T cells in the EphA2-positive renal cell carcinoma (10), and dendritic cell vaccination with EphA2 peptides has been applied in the clinical trial of glioblastoma multiforme (11).